S.E. Mukashev
Research Subjects
S.E. Mukashev has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- D.O. Bogdanova3 shared publications
- M.M. Sundetov3 shared publications
- Nazira Yerimova3 shared publications
- Shirtaev Bakhytzhan
Department of Thoracic and Pediatric Surgery, JSC "National Scientific Center of Surgery", Almaty, Kazakhstan. .
3 shared publications - A. Kanazov1 shared publication
Almaty Jsc
1 shared publication
Latest Publications
- 1 October 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 3,p. 25-28
SURGERY OF CONGENITAL BRONCHEECTASES IN CHILDREN AND ADULTS
The overwhelming majority of thoracic and pediatric surgeons are of the opinion that it is necessary to perform early surgeries for congenital bronchiectasis, since bronchial dilatation leads to infection of bronchial contents and repeated exacerbations of the inflammatory process, but some pediatricians express a reserved attitude to operations in childhood, adhering to long-term follow-up tactics. Purpose. To present statistical data on the situation of patients with congenital bronchiectasis of different age categories and to offer separate recommendations for the treatment and diagnosis of patients with congenital bronchiectasis. Material and methods. 433 patients with congenital bronchiectasis were operated in our clinic, which was 50.9% of all congenital lung malformations. The patients’ age ranged from 2 to 65 years. There were more children and adolescents (60.9%) than adults (39.1%). Results. The article presents the results of diagnostics and surgical treatment of 433 patients with congenital bronchiectasis. It was found that the immediate and long-term results of surgical treatment of children are better than those of adult patients
- 1 October 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 3,p. 25-28
SURGERY OF CONGENITAL BRONCHEECTASES IN CHILDREN AND ADULTS
The overwhelming majority of thoracic and pediatric surgeons are of the opinion that it is necessary to perform early surgeries for congenital bronchiectasis, since bronchial dilatation leads to infection of bronchial contents and repeated exacerbations of the inflammatory process, but some pediatricians express a reserved attitude to operations in childhood, adhering to long-term follow-up tactics. Purpose. To present statistical data on the situation of patients with congenital bronchiectasis of different age categories and to offer separate recommendations for the treatment and diagnosis of patients with congenital bronchiectasis. Material and methods. 433 patients with congenital bronchiectasis were operated in our clinic, which was 50.9% of all congenital lung malformations. The patients’ age ranged from 2 to 65 years. There were more children and adolescents (60.9%) than adults (39.1%). Results. The article presents the results of diagnostics and surgical treatment of 433 patients with congenital bronchiectasis. It was found that the immediate and long-term results of surgical treatment of children are better than those of adult patients
- 1 July 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 2,p. 37-41
PROBLEMS OF ANTIBIOTIC RESISTANCE IN CHILDREN AFTER LIVER TRANSPLANTATION
- 1 July 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 2,p. 37-41
PROBLEMS OF ANTIBIOTIC RESISTANCE IN CHILDREN AFTER LIVER TRANSPLANTATION
- 1 March 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 1,p. 55-59
THE USE OF INTRAVENOUS IBUPROFEN IN POSTOPERATIVE PERIOD
The article reflects the role of non-steroidal anti-inflammatory drugs in postoperative period. The study was conducted on the data of 94 operations of children aged from 10 months to 15 years (mean age 4.4 years). All patients of our center with esophagocoloplasty in the postoperative period received the drug «Intrafen» in injectable form, intravenously. Name of manufacturer of drug: GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET, A.S. (Turkey). The main active substance of this drug is Ibuprofen 400mg/4ml for intravenous injection. Patients were injected intravenous ibuprofen at therapeutically effective doses for a minimal period of time. After receiving positive reactions to the drug at the initial stage of treatment, the dose and frequency of taking the drug was adjusted individually for each patient. Objective. This work is dedicated to evaluate the role of the intravenous Ibuprofen in the postoperative period in surgical practice. Material and methods. The study included 94 pediatric patients with esophagocoloplasty. Age of patients: from 10 months to 15 years (mean age 4.4 years), of which: 90 (96%) patients had post-burn stricture of the esophagus; 3 (3%) patients with esophageal atresia; 1 (1%) patient with a short esophagus. The number of female children - 51 (54.3%) patients, male - 43 (45.7%) patients. Results. The total number of patients receiving intravenous Ibuprofen in the postoperative period was 94. The optimal dose showed a good therapeutic effect. At the optimal dosage of 20 mg/kg/day, two patients experienced intra-abdominal bleeding. Follow-up time: 2 weeks after esophagocoloplasty. Conclusion. In patients with esophagocoloplasty, preventive intravenous administration of Ibuprofen showed a good therapeutic result. Patients noted a decrease in pain, which in turn led to a decrease in the need for emergency analgesia.
- 1 March 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 1,p. 55-59
THE USE OF INTRAVENOUS IBUPROFEN IN POSTOPERATIVE PERIOD
The article reflects the role of non-steroidal anti-inflammatory drugs in postoperative period. The study was conducted on the data of 94 operations of children aged from 10 months to 15 years (mean age 4.4 years). All patients of our center with esophagocoloplasty in the postoperative period received the drug «Intrafen» in injectable form, intravenously. Name of manufacturer of drug: GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET, A.S. (Turkey). The main active substance of this drug is Ibuprofen 400mg/4ml for intravenous injection. Patients were injected intravenous ibuprofen at therapeutically effective doses for a minimal period of time. After receiving positive reactions to the drug at the initial stage of treatment, the dose and frequency of taking the drug was adjusted individually for each patient. Objective. This work is dedicated to evaluate the role of the intravenous Ibuprofen in the postoperative period in surgical practice. Material and methods. The study included 94 pediatric patients with esophagocoloplasty. Age of patients: from 10 months to 15 years (mean age 4.4 years), of which: 90 (96%) patients had post-burn stricture of the esophagus; 3 (3%) patients with esophageal atresia; 1 (1%) patient with a short esophagus. The number of female children - 51 (54.3%) patients, male - 43 (45.7%) patients. Results. The total number of patients receiving intravenous Ibuprofen in the postoperative period was 94. The optimal dose showed a good therapeutic effect. At the optimal dosage of 20 mg/kg/day, two patients experienced intra-abdominal bleeding. Follow-up time: 2 weeks after esophagocoloplasty. Conclusion. In patients with esophagocoloplasty, preventive intravenous administration of Ibuprofen showed a good therapeutic result. Patients noted a decrease in pain, which in turn led to a decrease in the need for emergency analgesia.